Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3517 - Predictive biomarkers to ramucirumab in Asian metastatic gastric cancer patients: Circulating angiogenic factors of VEGFR2 and neurophilin are predictive to ramucirumab efficacy in Asian recurrent/metastatic gastric cancer patients


08 Oct 2016


Poster Display


Seungtaek Lim


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


S. Lim1, S.J. Heo2, T.S. Kim2, H.J. Kwon3, J.H. Kim2, M.K. Jeong2, H.S. Kim2, S.H. Beom2, H.C. Chung2, S.Y. Rha2

Author affiliations

  • 1 Hematooncology, Yonsei University Wonju Christian Hospital, 220-701 - Wonju/KR
  • 2 Internal Medicine, Yonsei Cancer Center, 120-752 - Seoul/KR
  • 3 Hematooncology, Yonsei University Wonju Christian Hospital, Wonju/KR


Abstract 3517


We conducted an exploratory study to identify potential biomarkers to predict therapeutic effect of ramucirumab in combination with paclitaxel as a second line treatment for recurrent/metastatic Korean gastric cancer (GC) patients.


We retrospectively reviewed clinical efficacay and toxicity in 70 GC patients who received ramucirumab with weekly paclitaxel in an open-label expanded access program after failure to first line chemotherapy. To find potential biomarker of ramucirumab, we investigated the association between efficacy of ramucirumab and tissue molecular characteristics (EBV, MMR, HER2, EGFR, C-MET etc.). Also, we measured circulating biomarkers (VEGF, sVEGFR2, HGF, neuropillin-1, IL-8, and PIGF,) by ELISA method before and after treatment in a subset of patients (n = 44 vs. n = 14, respectively).


With the median follow up of 5.3 months (range 0.5 ∼ 10.5 months), the median progression free survival (PFS) was 4.1 months (95% CI, 3.3 ∼ 4.9 months), and median overall survival (OS) was not reached. Of the 55 evaluable patients, the overall response rate (ORR) was 14.5% (8 partial responses), and disease control rate was 74.5%. Although there was no difference in PFS, OS or ORR according to receptor status, higher DCR was found in patients with EGFR high expression tumors (2 + ∼3+) compared with low expression tumors (0 ∼ 1+) (87.5% vs. 50%, p = 0.02). Regarding circulating biomarkers related to angiogenesis, longer PFS was seen in patients with higher level of pretreatment serum VEGFR2 (4.1 vs. 2.4 months; p = 0.01) and lower level of pretreatment serum neuropillin-1 (5.8 vs. 2.4 months; p 


Current study suggested that circulating biomarkers related to angiogenesis quantified by ELISA method may predict prolonged response to ramucirumab in the treatment of gastric cancer patient.

Clinical trial identification

Legal entity responsible for the study





S.Y. Rha: Consulting or advisory role in 2years: Merck & Co.Inc. Speakers' Bureau in 2 years: Novartis, Eli Lilly, Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings